Porter SB, et al. - Through a retrospective review of 38,220 patients (8,877 high-risk cases) who underwent primary TKA and THA between 2011 and 2017, experts ascertained the risk of complications among high-risk and low-risk TKA and THA patients who were receiving tranexamic acid (TXA, its administration is done in order to decrease postoperative blood loss and this is a well-established practice for TKA and THA). Among high-risk patients who received TXA and high-risk patients who did not receive TXA, no important variation in the odds of these adverse outcomes was discovered. Also, no variations were noted when assessing the odds of 90-day postoperative deep vein thrombosis and pulmonary embolism nor myocardial infarction and cerebrovascular accident for high-risk patients receiving TXA compared with high-risk patients who did not receive TXA. Thus, TXA administration to high-risk TKA and THA patients is not correlated with a statistically important variation in adverse outcomes. Incremental evidence in support of TXA administration for high-risk individuals undergoing primary arthroplasties was presented.